{PAB) is a Melbourne-based developer of natural human antibodies for the treatment of cancer. The company has been built on technology to identify novel cancer targets, as well as produce monoclonal antibodies of the IgM class rather than the conventional IgG class to which all the current approved antibody drugs belong. Patrys is currently in Phase I/IIa trials with PAT-SM6 in Multiple Myeloma. PAT-LM1, for various solid tumours, is pre-clinical.
To date: 9 patients treated with 4 doses PAT-SM6 in 3 dose cohorts (0.3mg/kg, 1mg/kg, and 3mg/kg). 4th cohort (6mg/kg/dose) currently underway
o PAT-SM6 safe in all patients so far. No dose limiting toxicity (DLT), no related serious adverse events (SAE) and no related adverse event grade = 4
o 2 / 9 patients had stable disease (day +35 post treatment) with a significant reduction in protein M levels in the peripheral blood
o Median time to next therapy is 42 days (clinically significant). One patient has stable disease for 127 days post treatment
o 7 / 9 patients responded positively to drugs that they had previously been resistant to (i.e PAT-SM6 makes cancer cells more sensitive to other drugs)
Dr dax Calder bought 8 million shares on market in august Michael Stork Director has 85 million shares
